BioNTech SE (BNTX) Income Statement

NASDAQ: BNTXRevenue, profits, margins and EPS over 9 years.

BNTX 2025 at a glance

Fiscal year ended December 31, 2025 · euros
Revenue+0.2%
€2.76B
2025 · hover or tap a bar for each year
2017: €61.6M2018: €127.6M (+107.1%)2019: €108.6M (−14.9%)2020: €482.3M (+344.1%)2021: €18.98B (+3,834.6%)2022: €17.31B (−8.8%)2023: €3.82B (−77.9%)2024: €2.75B (−28.0%)2025: €2.76B (+0.2%)
20172025
Gross profit−3.2%
€2.14B
2025 · hover or tap a bar for each year
2017: €52.3M2018: €113.9M (+117.8%)2019: €91.2M (−19.9%)2020: €423.0M (+363.8%)2021: €16.07B (+3,697.9%)2022: €14.32B (−10.9%)2023: €3.22B (−77.5%)2024: €2.21B (−31.4%)2025: €2.14B (−3.2%)
20172025
Operating income
−€623.9M
2025 · hover or tap a bar for each year
2017: −€61.3M2018: −€53.9M2019: −€181.5M2020: −€82.4M2021: €15.28B2022: €12.64B (−17.3%)2023: €690.4M (−94.5%)2024: −€1.31B (−290.4%)2025: −€623.9M
20172025
Net income
−€1.09B
2025 · hover or tap a bar for each year
2017: −€85.7M2018: −€48.0M2019: −€179.1M2020: €15.2M2021: €10.29B (+67,613.8%)2022: €9.43B (−8.3%)2023: €930.3M (−90.1%)2024: −€665.3M (−171.5%)2025: −€1.09B
20172025
Net profit margin−15.4 pts
−39.6%
2025 · hover or tap a point for each year
2017: −139.1%2018: −37.6% (+101.4 pts)2019: −164.9% (−127.3 pts)2020: 3.2% (+168.1 pts)2021: 54.2% (+51.1 pts)2022: 54.5% (+0.3 pts)2023: 24.4% (−30.1 pts)2024: −24.2% (−48.5 pts)2025: −39.6% (−15.4 pts)
20172025

BNTX revenue and net income

RevenueNet incomeNet margin (right axis)

Where BNTX's revenue goes

2025
Revenue
€2.76B100.0%
Cost of revenue
−€616.5M−22.4%
Gross profit
€2.14B77.6%
Research & development
−€2.02B−73.3%
Sales, general & admin
−€698.2M−25.3%
Other operating expenses
−€44.0M−1.6%
Operating income
−€623.9M−22.6%
Interest & other expense
−€385.5M−14.0%
Income taxes
−€81.9M−3.0%
Net income
−€1.09B−39.6%

Each bar shows an amount and its share of revenue. BNTX kept −39.6% of revenue as net income.

BNTX profit margins

GrossOperatingNet

BNTX growth rates

to 2025
1 year3 years5 years10 years
Revenue+0.2%−45.8%+41.7%—
Gross profit−3.2%−46.9%+38.3%—
Operating income————
Net income————

1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.

BNTX income statement in euros

202520242023202220212020201920182017
Revenue€2.76B€2.75B€3.82B€17.31B€18.98B€482.3M€108.6M€127.6M€61.6M
Cost of revenue€616.5M€541.3M€599.8M€3.00B€2.91B€59.3M€17.4M€13.7M€9.3M
Gross profit€2.14B€2.21B€3.22B€14.32B€16.07B€423.0M€91.2M€113.9M€52.3M
Research & development€2.02B€2.25B€1.78B€1.54B€949.2M€645.0M€226.5M€143.1M€85.5M
Sales, general & admin€698.2M€599.0M€557.7M€481.7M€276.8M€95.6M€43.3M€27.1M€29.5M
Total operating expenses€2.76B€3.52B€2.53B€1.67B€781.4M€505.4M€272.7M€167.7M€113.6M
Operating income−€623.9M−€1.31B€690.4M€12.64B€15.28B−€82.4M−€181.5M−€53.9M−€61.3M
Interest income—€437.6M€357.6M€330.3M€1.5M€1.6M€1.8M€2.0M€2.1M
Interest expense€13.6M€13.2M€7.8M€15.8M€5.6M€1.9M€1.7M€1.8M€651,443
Income before taxes−€1.01B−€677.7M€1.19B€12.95B€15.05B−€145.8M−€179.4M−€47.7M−€85.9M
Income taxes€81.9M−€12.4M€255.8M€3.52B€4.75B−€161.0M−€200,000€600,000€45,000
Net income−€1.09B−€665.3M€930.3M€9.43B€10.29B€15.2M−€179.1M−€48.0M−€85.7M
EBITDA−€628.0M−€367.1M€1.38B€13.10B€15.00B−€105.1M−€143.8M−€24.0M−€74.7M
Gross margin77.6%80.3%84.3%82.7%84.7%87.7%84.0%89.3%84.9%
Operating margin−22.6%−47.8%18.1%73.0%80.5%−17.1%−167.1%−42.2%−99.5%
Net margin−39.6%−24.2%24.4%54.5%54.2%3.2%−164.9%−37.6%−139.1%

Quarterly columns are labeled by the month the quarter ended. Figures in euros as reported in BNTX's financial statements (latest annual report filed March 10, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.

BNTX financial results

In fiscal year 2025 (ended December 31, 2025), BioNTech reported revenue of €2.8 billion, up 0.2% from the year before. It had a net loss of €1.1 billion, a net profit margin of −39.6%. Over five years revenue grew at an average rate of 41.7% a year. Figures are in euros, the currency of its financial statements.

See the BNTX stock overview for the latest quote and news, or the BNTX chart for price history and technical indicators.

BNTX income statement FAQ

What is BioNTech's annual revenue?

BioNTech reported total revenue of €2.8 billion for fiscal year 2025, which ended on December 31, 2025. That was up 0.2% from €2.8 billion the previous year.

Is BioNTech profitable?

No. BioNTech reported a net loss of €1.1 billion in fiscal 2025, a net profit margin of −39.6%; its operating margin was −22.6%.

What is BioNTech's gross margin?

BioNTech's gross margin was 77.6% in fiscal 2025: for every $100 of revenue, BioNTech kept $78 after the direct cost of its products and services.

How much does BioNTech spend on research and development?

BioNTech spent €2.0 billion on research and development in fiscal 2025, 73.3% of revenue.

How fast is BioNTech growing?

Revenue grew 41.7% a year on average over the last five fiscal years, from €482.3 million to €2.8 billion.

When will BioNTech report its next earnings?

BioNTech is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens.

When does BioNTech's fiscal year end?

BioNTech's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 10, 2026.

Biotechnology income statements